Gilead's Genvoya wins EC nod; Valeant's problems weighing on share prices of Horizon, Mallinckrodt;

@FiercePharma: CBN: Multinational drugmakers face uphill battle in China. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: UPDATED: Pfizer finally gets its inversion with $160B Allergan megamerger agreement. Article | Follow @CarlyHFierce

> Gilead's ($GILD) 4-in-1 HIV treatment has won approval from the European Commission. Release

> Purdue Pharma, Johnson & Johnson ($JNJ), Endo ($ENDP), Allergan ($AGN) and Teva ($TEVA) have responded to the City of Chicago's second attempt to sue pain drugmakers for the costs of what Chicago says is a drug addiction epidemic. Report

> The questions that have led to the dramatic slide in the price of Valeant Pharmaceuticals' ($VRX) shares have taken a toll on the share of other companies such as Horizon Pharma ($HZNP) and Mallinckrodt ($MNK), companies often compared to Valeant. Story

> A Harvard-led panel of experts called the WHO response to the Ebola outbreak an "egregious failure." Report

> Bristol-Myers Squibb has added hep C drug Daklinza (daclatasvir) to the Medicines Patent Pool, allowing generic makers to produce it royalty free in low-income middle income countries. Release

Medical Device News

@FierceMedDev: ICYMI Friday: Bard to buy Liberator for $181M to improve access to home care market. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Scientific earns CE mark for second-gen Watchman implant to prevent stroke. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: Cancer diagnostics company closes up shop after 6-year FTC investigation. Article | Follow @EmilyWFierce

> Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device. More

> CardioDiagnostics gets in on patient monitoring with plans for $7M fundraise. Article

> Mindray Medical shells out $25M to settle pulse oximeter patent battle with Masimo. Story

Biotech News

@FierceBiotech: With Pfizer and Allergan set for a $160B megamerger, what becomes of R&D? Report | Follow @FierceBiotech

@JohnCFierce: So Ian Read remains CEO. Gets $AGN at a pretty decent price, Gets his Irish domicile. Looking for $2B in cuts. Read must be pretty chuffed. | Follow @JohnCFierce

@DamianFierce: I thought Ian Read would be taller. Item | Follow @DamianFierce

> Roche's blockbuster-hopeful immunotherapy shows promise in skin cancer. Report

> ObsEva taps A-list investors for $60M as pipeline nears late-phase trials. Article

Animal Health News

> Virginia Tech preps dog trial of new method to improve glioblastoma treatment. Report

> Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. More

> Oasmia chairman is optimistic about animal health despite downsized IPO. Story

> Kuddly joins herd of veterinary apps with $1.5M seed round. Item

> Taco Bell joins fast food peers with cage-free egg pledge. Article

Biotech IT News

> Molecular Health raises $27M to advance data-crunching tech. News

> Illumina to make 5,000-genome autism database available through BaseSpace. Report

> Amazon shares landmark cancer genome data sets on cloud platform. Story

> FDA gives scientists freedom to tweet in long-awaited social media policy. Item

> AstraZeneca inks deal to install robots at new R&D facility. Article

Pharma Marketing News

> Amgen nabs another PCSK9 exclusive, this time with giant CVS. Report

> Better together? Savvy e-patients may make pharma marketing smarter. Story

> Teva goes for laughs in new social media campaign for COPD. Item

> AstraZeneca aims at a 'broader' target with services-based lung cancer effort. Article

> Healthcare ad and media agencies break into annual 'best workplaces' ranking. More